Bromelanotide cas 189691-06-3 PT-141
Bremelanotide PT 141 189691-06-3 professional supplier
Specification:
Bremelanotide // PT141
Cas 189691-06-3
MW 1025.2 g/mol
Absrtact Bremelanotide (formerly PT-141) is a compound under drug development by Palatin Technologies as a treatment for female sexual dysfunction, hemorrhagic shock and reperfusion injury. It functions by activating the melanocortin receptors MC1R and MC4R, to modulate inflammation and limitingischemia. It was originally tested for intranasal administration in treating female sexual dysfunctionbut this application was temporarily discontinued in 2008 after concerns were raised over adverse side effects of increased blood pressure. As of March, 2012, Palatin is conducting a human Phase 2B study using a new subcutaneous drug delivery system that appears to have little effect on blood pressure.
Payment:
We recommend T/T or Escrow , D/P,D/A, or PayPal are also acceptable!
Delivery:
Express way as the following is:
(Shipping : TNT,Fedex,DHL,USP,EMS and so on)
Packaging:
Laboratory:
Our Company:
Our company advantage:
1.Small order is acceptable
2.Can provide sample for you
3.Have self-export rights
Exhibition:
The End |
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View